This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Orbit Discovery Appoints Dr Neil Butt as Chief Executive Officer

Orbit Discovery Appoints Dr Neil Butt as Chief Executive Officer

29 Jun 2021

Oxford, United Kingdom, June 29, 2021: Orbit Discovery Ltd (“Orbit”), a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil Butt as Chief Executive Officer. With an extensive track record in commercialising proprietary drug discovery platforms, Dr Butt joins Orbit to oversee the Company’s development into a service driven drug... Read more

Innovative herbicide discovery firm MoA Technology moves to TOSP

Innovative herbicide discovery firm MoA Technology moves to TOSP

28 Jun 2021

Innovative herbicide discovery firm MoA Technology moves to TOSP Third occupier for Bellhouse Building at The Oxford Science Park Oxford, UK, June 28 2021 – MoA Technology, which is focused on providing farmers with a diverse choice of innovative technologies for weed control, is the third occupier of the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies. The Oxford... Read more

ATDBio establishes molecular diagnostics lab to support customer research

ATDBio establishes molecular diagnostics lab to support customer research

21 Jun 2021

ATDBio establishes molecular diagnostics lab to support customer research Leading nucleic acid maker evolves activity & builds on pandemic experience    Oxford, UK, June 21 2021 – ATDBio, a leading innovative manufacturer of synthetic DNA and RNA oligonucleotides, has established a new 745 sq ft molecular diagnostics research and quality control laboratory at The Oxford Science Park. Driven by its experience during the... Read more

Exscientia acquires personalised medicine AI pioneer Allcyte

Exscientia acquires personalised medicine AI pioneer Allcyte

15 Jun 2021

Deep learning platform evaluates drug activity in patient tumour microenvironments with single cell resolution First AI platform clinically validated to improve treatment outcomes in prospective study Exscientia, a clinical stage pharmatech company, has entered into a binding agreement to acquire Allcyte, a leader in artificial intelligence (AI) based precision medicine.  The combination expands Exscientia’s translational capabilities... Read more

OBN Announce the 2020 OBN Award winners

OBN Announce the 2020 OBN Award winners

14 Jun 2021

We are delighted to announce the winners of the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London. The Awards, which are in their 12th year, shine a light on companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical need, outstanding company progression and the delivery of real-life... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More